Intermittent claudication (IC) is the major clinical manifestation of peripheral arterial disease (PAD). Apoptosis has been linked to skeletal muscle pathophysiology in other chronic diseases such as congestive heart failure. This study tested the hypothesis that there would be increased levels of apoptosis in the skeletal muscle of patients with PAD compared with control individuals. In total, 26 individuals with PAD and 28 age-appropriate controls underwent studies of peak oxygen consumption (peak VO 2 ) and a gastrocnemius muscle biopsy in the most symptomatic leg. Muscle biopsies were analyzed for apoptosis and caspase-3 activity. Patients with PAD had a reduced peak VO 2 compared with controls. Apoptosis was increased in those with PAD compared with age-appropriate controls (3.83% Ϯ 2.6 vs 1.53% Ϯ 0.96; p Ͻ 0.001). In conclusion, PAD is associated with increased levels of apoptosis in the peripheral skeletal muscle. Further study is required to ascertain whether apoptosis plays a role in decreased functional capacity.
Introduction
Peripheral arterial disease (PAD), when symptomatic with intermittent claudication (IC), is associated with severe limitations in the ability to carry out normal daily activities and leads to severely impaired healthrelated quality of life (HRQOL). 1 On average, patients with claudication have a peak oxygen consumption that is 50% of age-matched normal individuals, and this level of impairment is similar to patients with New York Heart Association class III heart failure. 2 Pharmacologic therapies in PAD are very limited. 3 Although the principal cause of IC is reduced blood flow to the lower limbs relative to increased demand during exercise, the pathophysiology of IC is not completely understood. For example, limb hemodynamics do not closely correlate with clinical presentation or the limitations in peak exercise performance. Hemodynamic measures of the severity of PAD, such as the ankle-brachial systolic blood pressure index (ABI) and blood flow by strain gauge plethysmography, are poor predictors of exercise capacity in patients with IC. The surgical correction of lower extremity blood flow in patients with IC does not always lead to completely improved exercise tolerance [4] [5] [6] and even when changes in limb blood flow are detected these changes do not provide a strong prediction of the clinical response. 6 Exercise training, which does improve exercise tolerance consistently, has been shown to improve limb blood flow in some but not all studies. Therefore, when taken together, factors other than limitations in blood flow likely contribute to the pathogenesis of PAD. 3 Biopsy studies from patients with PAD have demonstrated alterations in fiber type distribution, denervation and alterations in muscle metabolism. 5, 7, 8 One potential skeletal muscle alteration in PAD is apoptosis. Apoptosis is defined as programmed cell death. In the myocardium, elevated levels of apoptosis are associated with, and are likely to be a contributor of, poor left ventricular performance in patients with congestive heart failure. [9] [10] [11] Human studies have described increased skeletal muscle apoptosis in a variety of diseases, including mitochondrial myopathies, amyotrophic lateral sclerosis, chronic obstructive lung disease, and congestive heart failure. 12, 13 In these diseased populations, increases in skeletal muscle apoptosis appear to be inversely related to exercise capacity. 14 To our knowledge, no study has sought to determine whether apoptosis occurs in the skeletal Increased levels of apoptosis in gastrocnemius skeletal muscle in patients with peripheral arterial disease muscle of patients with PAD. Therefore, this study tested the hypothesis that apoptosis is present at increased levels in the gastrocnemious muscle of PAD patients compared with age-appropriate controls.
Methods

Participant selection
Fifty-four individuals were studied (PAD ϭ 26, ageappropriate controls ϭ 28). Participants were recruited from the Duke University Medical Center and the University of Colorado Denver and Health Science Center vascular clinics and community. The inclusion criteria for the PAD patients were: ABI Ͻ 0.90 at rest, exercise limited by claudication, not currently performing regular exercise, and receiving a stable medical regimen including statin, anti-platelet, and antihypertensive therapies, as clinically indicated. In one PAD patient, ABI values were unobtainable due to non-compressible vessels and inclusion was based on angiography-documented arterial occlusive disease. Patients with PAD were excluded if medical history indicated critical limb ischemia, severe peripheral neuropathy, revascularization within 3 months, unstable angina or severe (Ͼ70%) three coronary vessel disease, diabetes, or any reason that would not allow exercise training. Age-appropriate control individuals were sedentary, free of symptomatic coronary disease as indicated by physical exam, history and ECG tracing. Controls had ABI values above 1.00 and all women participants were postmenopausal. All studies were performed under research protocols approved by the Duke University and University of Colorado Denver and Health Sciences Center Institutional Review Boards. Each individual was informed of testing protocols and the potential risks and benefits of participation. All individuals provided written informed consent before participation.
Exercise testing
All individuals underwent a maximal cardiopulmonary exercise test (CPX) with a 12-lead ECG and expired gas analysis on a treadmill. CPX testing was performed to investigate a potential link between the severity of muscle alterations in PAD (compared with age-appropriate controls) and maximal functional capacity. The Gardner protocol, which maintains 2 mph (3.08 Km/h) speed, with a 2% grade increase every 2 minutes, was used for 24 PAD patients. An augmented protocol starting at 1.9 mph (2.92 Km/h) and 10% grade increasing 0.4 mph (0.62 Km/h) and 2% grade every 2 minutes was used for two PAD patients who were able to walk longer than 10 minutes on the Gardner protocol. These tests were performed twice at baseline for PAD patients and the results from the test with the highest peak oxygen consumption (peak VO 2 ) value was used in the analysis. Expired gases were analyzed continuously using a ParvoMedics unit (Sandy, UT, USA) at Duke University or a MedGraphics CPX/D (Medical Graphics Corp., St Paul, MN, USA) at the University of Colorado Denver and Health Science Center and averaged in 15-second intervals. The highest value achieved during exercise was used to determine peak VO 2 . The Gardner protocol is specifically designed for a claudication-limited PAD population. Therefore, an alternative protocol was necessary to evaluate maximal functional capacity in the age-appropriate controls. The Storey protocol, consisting of 2-minute stages, which increases in workload by approximately 1 MET ϭ metabolic equivalent, (1 MET is approximately 3.5 ml/kg/min) per stage, was used.
Skeletal muscle biopsies
Biopsy samples were obtained from the medial side of the gastrocnemious muscle at a minimum of 24 hours after the CPX. This was done in order to ensure that the skeletal muscle was in a resting metabolic state. Biopsy sites were anesthetized with a 2% lidocaine solution, and 1.0-cm incisions were made through the skin and gastrocnemius fascia. A modified Bergstrom needle technique was inserted 10-15 mm and used to obtain 40-50 mg of skeletal muscle. 15 Samples were mounted, in cross-section, in optimal cutting temperature compound beds (Miles Pharmaceutical, West Haven, CT, USA), and snap frozen at -800°C and stored for analysis. 15 Histology analyses for apoptosis Apoptotic cells were determined by Terminal Deoxynucleotidyl Transferase Biotinman-dUTP Nickend Labeling (TUNEL). An in situ nick-end labeling apoptosis kit ApopTag (Intergen Company, Purchase, NY) was used to label apoptotic cells in skeletal muscle of histological section, as described. 16 This method labeled fragmented DNA using terminal deoxynucleotidyl transferase (TdT) with digoxigeninconjugated peroxidase staining and a methyl green counterstain, as described by the manufacturer's instructions. Positive control slides were pretreated with DNase I (Sigma) at 100 ng ml Ϫ1 for 10 minutes at room temperature, followed by end labeling. Negative controls were performed without active TdT. The apoptotic index was expressed by the percentage of the number of positive nuclei divided by the total number of counted nuclei. The count was performed on three randomly selected fields (magnification 100ϫ), and at least 200 nuclei per sample. A single reader blinded to the sample type performed all the analyses.
In randomly selected blinded sub-samples (n ϭ 20; 10 PAD and 10 controls), TUNEL staining was followed by immunohistochemistry (double staining) to identify endothelial cell-specific apoptosis. To identify endothelial cells, CD31 (a mouse monoclonal antibody Biogenex, cat #AM232-5M), 16 designed for the specific localization of human endothelium in normal and tumor tissue was used. Slides were brought to room temperature, placed in ice-cold acetone for 2 minutes and PBS for 5 minutes. Blocking solution (10% horse serum in PBS) was applied for 1 hour at room temperature. The primary antibodies were applied for 1 hour followed by sequential incubation with a biotinylated anti-mouse IgG and ABC reagent, according to the manufacturer's specifications (Vectastain ABC kit; Vector Laboratories, Burlingame, CA). 16 Levamisole was added to block endogenous alkaline phosphatase activity and immune complexes were localized using the chromogenic alkaline phosphatase substrate Vector Red (Vector Laboratories). When counterstained with hematoxolin, dehydrated and mounted with Permount (Fisher Scientific, Pittsburgh, PA), the antigen appeared red and the nuclei blue. Cells that double stain positively for CD31 and apoptosis appear blue and brown with the red antigen identifying CD31-positive cells. A murine IgG monoclonal antibody served as a negative control.
Caspase-3 activity was measured to determine enzymatic evidence of apoptosis. Gastrocnemius muscle (10 mg) was homogenized in a 1 M tris buffer at a pH of 7.5 and incubated on ice for 10 minutes and then centrifuged for 1 minute in a microcentrifuge at 10,000ϫ g. The supernatant was put in a fresh tube and put on ice. After the protein concentration was determined on the lysate, the lysate was titrated to a protein concentration of 1-4 g l Ϫ1 . Next, 50 l of lysate supernatant was put into a separate tube and 50 l of 2ϫ reaction buffer (containing 10 mM DTT) was added to each sample. Then, 5 l of the 4 mM acetyl-Asp-Glu-Val-Asp-p-nitroanilide (DEVD-pNA) substrate (200 M final conc.) was added to each sample and incubated at 37°C for 1-2 hours. Finally, we promptly read the samples at 400 nm or 405 nm in a spectrophotometer using a 100-l micro quartz cuvet (Sigma).
Statistical analysis
The groups were matched for age and sex. Differences between the PAD patients and age-appropriate control individuals were determined using the Student's t-test for continuous variables and chi-square for percent yes/no. A Pearson correlation was performed between measures of functional capacity and apoptosis. All tabular data are presented as mean Ϯ SD and data in all figures are presented as mean Ϯ SE. P-values of Ͻ0.05 were considered significant for all tests.
Results
The baseline demographic and clinical characteristics are shown in Table 1 . As expected, those with PAD had lower mean ABI values (0.60 Ϯ 0.18 while controls had mean values of 1.12 Ϯ 0.09; p Ͻ 0.001) and had significant functional impairment as measured by peak VO 2 (15.90 Ϯ 4.03 ml kg Ϫ1 min Ϫ1 vs 24.73 Ϯ 6.04 ml kg Ϫ1 min Ϫ1 ; p Ͻ 0.001) compared with the age-appropriate controls. One PAD patient with noncompressible vessels was not included in the ABI calculation. Patients with PAD achieved a peak walking time of 514.9 Ϯ 316.3 seconds and a claudication onset time of 189.4 Ϯ 212.2 seconds. Means for peak walking time and claudication onset time are only presented for 24 of 26 PAD patients who were tested on the Gardner protocol. Those with PAD had a greater history of smoking and were more often on statin medications than age-appropriate control individuals.
The fraction of TUNEL-positive nuclei was greater in PAD patients versus age-appropriate controls (Figure 1 vs Figure 2 ). TUNEL-positive nuclei could be detected in 3.83% Ϯ 2.7% of the total skeletal muscle nuclei of PAD patients versus 1.53% Ϯ 0.96% of age-appropriate controls (p Ͻ 0.001) (Figure 3 ). In randomly selected, blinded sub-samples (n ϭ 20; 10 PAD and 10 ageappropriate controls), double staining for endothelial nuclei and apoptotic nuclei revealed that an increased amount of apoptotic nuclei in PAD patients (Figure 1) were endothelial in origin compared with age-appropriate controls (Figure 2 ) (38.3% Ϯ 2.5% vs 18.5% Ϯ 4.2%; p Ͻ 0.001). In this sub-sampled group, endothelial cells represented 5.2% Ϯ 1.3% of the total nuclei counted in PAD patients vs 4.8% Ϯ 1.1% for age-appropriate control individuals. The mean number of total skeletal muscle nuclei was similar between those with PAD and age-appropriate controls (99.5 Ϯ 31.8 vs 103.1 Ϯ 32.3). Neither smoking status nor statin therapy had a significant effect on skeletal muscle apoptosis within the PAD patients or between age-appropriate controls and PAD groups. However, a significant difference in apoptosis remained when non-smoking PAD and non-smoking age-appropriate controls were compared ( p Ͻ 0.01).
In addition to increases in TUNEL-positive nuclei, caspase-3 activity (Figure 4) , the final enzymatic step in the apoptosis pathway, was measured in a randomly selected blinded sub-sample of 20 individuals (PAD ϭ nine, age-appropriate controls ϭ 11). Caspase-3 activity was significantly increased in PAD patients compared with age-appropriate controls Within the PAD group, apoptosis did not correlate with the function markers peak VO 2 , ABI, onset of claudication pain or peak walking time.
Discussion
Intermittent claudication caused by atherosclerotic vascular disease is a major health care problem but the pathophysiology of this disease is not completely understood. Apoptosis, programmed cell death, is a tightly regulated process that is increased in frequency in the setting of pathologic conditions. The major finding of this study was an increased level of apoptosis in the gastrocnemius skeletal muscle of patients with PAD compared to age-appropriate controls. In addition, a greater fraction of endothelial cells exhibited cell death in PAD patients than would be expected based on their frequency. Although apoptosis plays a critical role in neonatal/pediatric development, in the adult apoptosis is generally regarded as playing a role in a limited number of normal physiologic processes, such as menstruation and wound healing. 11 Terminally differentiated cells within muscle should have low rates of apoptosis under normal conditions. 9 Therefore, it is unlikely that increased rates of apoptosis occur in a normal physiologic setting. It is of interest to note that in our current report slightly over 1% of the nuclei in age-appropriate individuals were TUNEL positive and this value is in close agreement with other reports concerning the muscle of age-appropriate individuals. 10, 13, 17 Two prior reports using histological and immunohistochemical methods to examine skeletal muscle, one in a pre-clinical model of PAD and one in patients with congestive heart failure, have shown increases in apoptosis when compared with controls. 12, 16 These previous findings suggest that a variety of cardiovascular disorders are associated with apoptosis. In our current report, we used histologic and enzymatic assays to demonstrate increases in apoptosis in individuals with PAD. A number of different cell types including but not limited to myocytes, endothelial, vascular smooth muscle, fibroblasts, and adventitial, nerve, and satellite cells are likely present in the biopsy obtained. Based on a prior paper, 18 we chose to examine endothelial cells as this cell type showed an increased fraction of apoptotic nuclei in a pre-clinical model of PAD. We examined a random subgroup of samples and by histology 38.3% of the apoptotic nuclei in patients with PAD were endothelial in origin versus 18.5% in age-appropriate controls. Our data do not exclude the possibility that other cell types could have higher rates of apoptosis as well. These findings raise the possibility that endothelial cells in skeletal muscle may be more susceptible to apoptosis than other cell types. 16 Whether this increase in apoptosis is due to primary ischemic injury of the microvascular endothelium or an increased susceptibility of these cells to paracrine injury will need to be explored.
Interestingly, in our sample population, we did not detect a correlation between levels of apoptosis and functional markers or hemodynamic disease severity within the PAD patients. This does not necessarily mean that a relationship does not exist. There are a number of potential reasons to explain this null finding. It is possible that the current study is not powered to detect such a relationship or that the relationship may differ among sub-populations. Further investigation will be needed to delineate the different molecular pathways involved in apoptosis and the functional significance of this finding to advance therapies in PAD.
Figure 3
A comparison of apoptosis in PAD patients compared with age-appropriate control individuals. Apoptosis in PAD patients was greater than ageappropriate controls (*denotes p Ͻ 0.001).
Figure 4
A comparison of caspase-3 activity in patients with PAD versus age-appropriate control individuals. PAD patients had greater caspase-3 activity (enzymatic confirmation of apoptosis) than age-appropriate controls (*denotes p Ͻ 0.001).
